{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:09:50Z","timestamp":1784282990952,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multidisciplinary care (MDC), where a team of various health professionals provides guidance to patients, is an effective approach for chronic kidney disease (CKD) and has been reimbursed by Japanese public healthcare insurance in 2024. To sustainably achieve medical benefits with limited resources, we examined the cost-effectiveness of MDC in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model from a healthcare system perspective was used to evaluate the cost-effectiveness of adding MDC to the standard treatment for CKD in Japan over lifetime. Each cohort with an initial CKD stage (G3a, G3b, and G4) was analyzed. The parameters were based on previous studies including Chronic Kidney Disease Japan Cohort study. An incremental cost-effectiveness ratio (ICER) of\u2009&lt;\u20095,000,000 Japanese yen (JPY) per quality-adjusted life-year (QALY) was considered cost-effective. One-way deterministic analyses, probabilistic sensitivity analyses, and scenario analyses were conducted to ensure the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adding MDC to the standard treatment for CKD decreased cost by 10.66 million, 8.42 million, 4.21 million JPY and increased utility by 9.52, 8.70, 7.17 QALYs in CKD G3a, G3b, and G4 cohort, respectively, suggesting that it was a dominant strategy. Sensitivity analyses showed that adding MDC was cost-effective in more than 99% of cases in all cohorts with an ICER threshold of 5,000,000 JPY. Scenario analyses, where smaller therapeutic effects of MDC were estimated, showed compatible results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on our model, adding MDC to the standard treatment for CKD stages G3a, G3b, and G4, is highly likely to be a cost-effective strategy in Japanese healthcare system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02883-0","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:49:22Z","timestamp":1779112162000},"page":"1185-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan"],"prefix":"10.1007","volume":"30","author":[{"given":"Hiromu","family":"Tomishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Odawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuguru","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-7889","authenticated-orcid":false,"given":"Hiroshi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"7","key":"2883_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385. https:\/\/doi.org\/10.1038\/s41581-024-00820-6.","journal-title":"Nat Rev Nephrol"},{"issue":"10225","key":"2883_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3.","journal-title":"Lancet"},{"key":"2883_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102615","volume":"72","author":"S Chadban","year":"2024","unstructured":"Chadban S, Ar\u0131c\u0131 M, Power A, et al. Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102615. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102615.","journal-title":"EClinicalMedicine"},{"issue":"4S","key":"2883_CR4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"15","key":"2883_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"2883_CR6","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"23","key":"2883_CR7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"2","key":"2883_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"12","key":"2883_CR9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1253\/circj.CJ-22-0086","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I. Cost-effectiveness of Dapagliflozin for chronic kidney disease in Japan. Circ J. 2022;86(12):2021\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-22-0086.","journal-title":"Circ J"},{"issue":"1","key":"2883_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.0000000582","volume":"20","author":"M Odawara","year":"2025","unstructured":"Odawara M, Nishi H, Kodera S, Kondo M, Nangaku M. Cost-effectiveness of Empagliflozin in CKD with or without albuminuria. Clin J Am Soc Nephrol. 2025;20(1):50\u201361. https:\/\/doi.org\/10.2215\/CJN.0000000582.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2883_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/2054358119882667","volume":"6","author":"D Collister","year":"2019","unstructured":"Collister D, Pyne L, Cunningham J, et al. Multidisciplinary chronic kidney disease clinic practices: a scoping review. Can J Kidney Health Dis. 2019;6:2054358119882667. https:\/\/doi.org\/10.1177\/2054358119882667.","journal-title":"Can J Kidney Health Dis"},{"issue":"2","key":"2883_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000728","volume":"3","author":"JW Stanifer","year":"2018","unstructured":"Stanifer JW, Von Isenburg M, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health. 2018;3(2):e000728. https:\/\/doi.org\/10.1136\/bmjgh-2018-000728.","journal-title":"BMJ Glob Health"},{"key":"2883_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/20543581221077505","volume":"9","author":"V Nkunu","year":"2022","unstructured":"Nkunu V, Wiebe N, Bello A, et al. Update on existing care models for chronic kidney disease in low- and middle-income countries: a systematic review. Can J Kidney Health Dis. 2022;9:20543581221077505. https:\/\/doi.org\/10.1177\/20543581221077505.","journal-title":"Can J Kidney Health Dis"},{"issue":"6","key":"2883_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s10157-023-02338-w","volume":"27","author":"M Abe","year":"2023","unstructured":"Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S. Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study. Clin Exp Nephrol. 2023;27(6):528\u201341. https:\/\/doi.org\/10.1007\/s10157-023-02338-w.","journal-title":"Clin Exp Nephrol"},{"key":"2883_CR15","unstructured":"Ministry of Health, Labour and Welfare. Regarding Individual Revision Items (in Japanese), 2024. Accessed September 12, 2025. https:\/\/www.mhlw.go.jp\/content\/12404000\/001220531.pdf."},{"issue":"3","key":"2883_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002532","volume":"15","author":"E Lin","year":"2018","unstructured":"Lin E, Chertow GM, Yan B, Malcolm E, Goldhaber-Fiebert JD. Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: a modeling study. PLoS Med. 2018;15(3):e1002532. https:\/\/doi.org\/10.1371\/journal.pmed.1002532.","journal-title":"PLoS Med"},{"issue":"8","key":"2883_CR17","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2024.05.012","volume":"9","author":"M Paffett","year":"2024","unstructured":"Paffett M, Phannajit J, Chavarina KK, et al. Economic evaluation of an integrated care program compared to conventional care for patients with chronic kidney disease in rural communities of Thailand. Kidney Int Rep. 2024;9(8):2546\u201358. https:\/\/doi.org\/10.1016\/j.ekir.2024.05.012.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2883_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0158-6","volume":"16","author":"TS Johns","year":"2015","unstructured":"Johns TS, Yee J, Smith-Jules T, Campbell RC, Bauer C. Interdisciplinary care clinics in chronic kidney disease. BMC Nephrol. 2015;16(1):161. https:\/\/doi.org\/10.1186\/s12882-015-0158-6.","journal-title":"BMC Nephrol"},{"issue":"5","key":"2883_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3109\/09638280903171584","volume":"32","author":"C Sabariego","year":"2010","unstructured":"Sabariego C, Grill E, Brach M, Fritschka E, Mahlmeister J, Stucki G. Incremental cost-effectiveness analysis of a multidisciplinary renal education program for patients with chronic renal disease. Disabil Rehabil. 2010;32(5):392\u2013401. https:\/\/doi.org\/10.3109\/09638280903171584.","journal-title":"Disabil Rehabil"},{"issue":"1","key":"2883_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-018-0678-7","volume":"18","author":"S Hiragi","year":"2018","unstructured":"Hiragi S, Tamura H, Goto R, Kuroda T. The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling. BMC Med Inform Decis Mak. 2018;18(1):94. https:\/\/doi.org\/10.1186\/s12911-018-0678-7.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"2883_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1291\/hypres.31.1101","volume":"31","author":"E Imai","year":"2008","unstructured":"Imai E, Matsuo S, Makino H, et al. Chronic kidney disease Japan cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008;31(6):1101\u20137. https:\/\/doi.org\/10.1291\/hypres.31.1101.","journal-title":"Hypertens Res"},{"issue":"6","key":"2883_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10157-010-0328-6","volume":"14","author":"E Imai","year":"2010","unstructured":"Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol. 2010;14(6):558\u201370. https:\/\/doi.org\/10.1007\/s10157-010-0328-6.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2883_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2016.09.015","volume":"91","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Watanabe T, Takeuchi A, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91(1):227\u201334. https:\/\/doi.org\/10.1016\/j.kint.2016.09.015.","journal-title":"Kidney Int"},{"issue":"4","key":"2883_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422\u201337. https:\/\/doi.org\/10.1002\/hec.1481.","journal-title":"Health Econ"},{"issue":"3","key":"2883_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health. 2017;20(3):372\u20138. https:\/\/doi.org\/10.1016\/j.jval.2016.08.726.","journal-title":"Value Health"},{"issue":"1","key":"2883_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351. https:\/\/doi.org\/10.1016\/j.jval.2019.10.005.","journal-title":"Value Health"},{"issue":"6","key":"2883_CR27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41440-020-00608-8","volume":"44","author":"T Imaizumi","year":"2021","unstructured":"Imaizumi T, Hamano T, Fujii N, et al. Cardiovascular disease history and \u03b2-blocker prescription patterns among Japanese and American patients with CKD: a cross-sectional study of the CRIC and CKD-JAC studies. Hypertens Res. 2021;44(6):700\u201310. https:\/\/doi.org\/10.1038\/s41440-020-00608-8.","journal-title":"Hypertens Res"},{"key":"2883_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.7","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013130. https:\/\/doi.org\/10.1038\/kisup.2012.73.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2883_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1744-9987.2011.01005.x","volume":"16","author":"K Yamagata","year":"2012","unstructured":"Yamagata K, Nakai S, Masakane I, et al. Ideal timing and predialysis nephrology care duration for dialysis initiation: from analysis of Japanese dialysis initiation survey. Ther Apher Dial. 2012;16(1):54\u201362. https:\/\/doi.org\/10.1111\/j.1744-9987.2011.01005.x.","journal-title":"Ther Apher Dial"},{"issue":"6","key":"2883_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/1744-9987.12378","volume":"19","author":"I Masakane","year":"2015","unstructured":"Masakane I, Nakai S, Ogata S, et al. An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial. 2015;19(6):540\u201374. https:\/\/doi.org\/10.1111\/1744-9987.12378.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"2883_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10157-011-0567-1","volume":"16","author":"M Kondo","year":"2012","unstructured":"Kondo M, Yamagata K, Hoshi SL, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16(2):279\u201391. https:\/\/doi.org\/10.1007\/s10157-011-0567-1.","journal-title":"Clin Exp Nephrol"},{"issue":"2-3","key":"2883_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10754-007-9017-8","volume":"7","author":"S Fukuhara","year":"2007","unstructured":"Fukuhara S, Yamazaki C, Hayashino Y, et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ. 2007;7(2\u20133):217\u201331. https:\/\/doi.org\/10.1007\/s10754-007-9017-8.","journal-title":"Int J Health Care Finance Econ"},{"issue":"4","key":"2883_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s10157-010-0304-1","volume":"14","author":"R Tajima","year":"2010","unstructured":"Tajima R, Kondo M, Kai H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14(4):340\u20138. https:\/\/doi.org\/10.1007\/s10157-010-0304-1.","journal-title":"Clin Exp Nephrol"},{"key":"2883_CR34","doi-asserted-by":"publisher","unstructured":"Takura T, Hiramatsu M, Nakamoto H, et al. Health economic evaluation of peritoneal dialysis based on cost-effectiveness in Japan: a preliminary study. Clinicoecon Outcomes Res. 2019;11:579\u2013590. Published 2019 Sep 25. https:\/\/doi.org\/10.2147\/CEOR.S212911.","DOI":"10.2147\/CEOR.S212911"},{"issue":"3","key":"2883_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.transproceed.2019.01.049","volume":"51","author":"S Hiragi","year":"2019","unstructured":"Hiragi S, Goto R, Tanaka Y, et al. Estimating the net utility gains among donors and recipients of adult living donor kidney transplant. Transplant Proc. 2019;51(3):676\u201383. https:\/\/doi.org\/10.1016\/j.transproceed.2019.01.049.","journal-title":"Transplant Proc"},{"issue":"3","key":"2883_CR36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s10157-016-1309-1","volume":"21","author":"D Inaguma","year":"2017","unstructured":"Inaguma D, Imai E, Takeuchi A, et al. Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Clin Exp Nephrol. 2017;21(3):446\u201356. https:\/\/doi.org\/10.1007\/s10157-016-1309-1.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02883-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:58:56Z","timestamp":1784282336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02883-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02883-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consultancies: Masaomi Nangaku (Kyowa Kirin, Astellas, Astra Zeneca, GSK, Daiichi Sankyo, Tanabe Pharma, Chugai, Torii, Japan Tobacco, Novo Nordisk, Boehringer Ingelheim), Honoraria: Motoki Odawara (Kyowa Kirin), Tsutomu Sakurada (Vantive), Masaomi Nangaku (Kyowa Kirin, Tanabe Pharma, Bayer, Boehringer Ingelheim), Hiroshi Nishi (Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kowa, Kyowa Kirin, Tanabe Pharma, Mochida, MSD, Novartis, Novo Nordisk, Ono, Roche Diagnostics, Torii, Zeria), Grants received: Masaomi Nangaku (Kyowa Kirin, Japan Tobacco, Chugai, Boehringer Ingelheim), Hiroshi Nishi (Bayer, Boehringer Ingelheim, Kyowa Kirin, Novo Nordisk, Tanabe Pharma).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Nihon University School of Medicine (2025\u201320) and University of Tokyo Faculty of Medicine (2025111NIe) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}